28 Mar 2024 09:12
MGC Pharmaceuticals Ltd.
PDMR Notification
28 March 2024
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to advise that the following Persons Discharging Managerial Responsibilities (PDMR) were issued a combined 240,000 unlisted options as approved at a meeting of shareholders on 18 March 2024. This notification is made in accordance the UK Market Abuse Regulations.
1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
(a) | Name | Daniel Robinson | |||
2 | Reason for the notification
| ||||
(a) | Position
| Non-Executive Director | |||
(b) | Initial notification/amendment
| Initial | |||
(c) | If amendment: reason
| n/a | |||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
Full name of entity | MGC Pharmaceuticals Limited
| ||||
Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
(a) | Description of the financial instrument, type of instrument | Unlisted options exercisable at A$0.42 on or before 28 March 2027. | |||
(b) | Identification Code (ISIN)
| AU000000MXC6 | |||
(c) | Nature of transaction | Grant of Options over Ordinary Shares | |||
(d) | Currency | Price | Volume | Total | |
AUD | 0.00 | 120,000 | N/A | ||
Aggregated information | |||||
AUD | 0.00 | 120,000 | N/A | ||
(e) | Date of transaction
| 28 March 2024 | |||
(f) | Place of transaction
| Outside a trading venue | |||
1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
(a) | Name | Layton Mills | |||
2 | Reason for the notification
| ||||
(a) | Position
| Non-Executive Director | |||
(b) | Initial notification/amendment
| Initial | |||
(c) | If amendment: reason
| n/a | |||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
Full name of entity | MGC Pharmaceuticals Limited
| ||||
Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
(a) | Description of the financial instrument, type of instrument | Unlisted options exercisable at A$0.42 on or before 28 March 2027. | |||
(b) | Identification Code (ISIN)
| AU000000MXC6 | |||
(c) | Nature of transaction | Grant of Options over Ordinary Shares | |||
(d) | Currency | Price | Volume | Total | |
AUD | 0.00 | 120,000 | N/A | ||
Aggregated information | |||||
AUD | 0.00 | 120,000 | N/A | ||
(e) | Date of transaction
| 28 March 2024 | |||
(f) | Place of transaction
| Outside a trading venue | |||
-Ends-
Authorised for release by the Company Secretary, for further information please contact:
MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6555 2950 info@mgcpharma.co.uk | MGC Pharmaceuticals Ltd Rowan Harland Company Secretary +61 8 6555 2950 info@mgcpharma.co.uk
|
UK IR/PR Advisers IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen +44 203 934 6630 mgcpharma@investor-focus.co.uk | UK Brokers Oberon Capital Aimee McCusker / Adam Pollock +44 203 179 5300 aimeemccusker@oberoninvestments.com adampollock@oberoninvestments.com |